This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "Julphar" – news · newspapers · books · scholar · JSTOR (May 2012) (Learn how and when to remove this template message) A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (May 2012) (Learn how and when to remove this template message) (Learn how and when to remove this template message)
Julphar
Company typePublic shareholding company
ADX: JULPHAR
IndustryPharmaceuticals
Founded1980; 44 years ago (1980)
HeadquartersRas Al Khaimah, UAE
Area served
Worldwide
Key people
Sheikh Saqer Humaid Al Qasimi
(Chairman)
Jerome Carle
(CEO)[1]
RevenueIncrease AED 1.43 billion (2014)[2]
Increase AED 238.5 million (2014)
Increase AED 234.7 million (2014)
Number of employees
5,000[3]
Websitewww.julphar.net

Julphar is an Emirati pharmaceutical manufacturer in the Middle East.[4] Headquartered in Ras Al Khaimah, United Arab Emirates, the company employs more than 5,000 people and distributes its pharmaceutical products internationally. The company has three divisions — General Medicines, Julphar Diabetes Solutions and Julphar Life. In 2018, the company was ranked as the number one pharmaceutical manufacturer in the UAE.[5]

History

Julphar was established in 1980. The company obtained Ministry of Health approval for its first 30 products four years later and began manufacturing liquids and semi-solids in 1988. In 1990, distribution agents were established in key markets across the globe and work began on the construction of new manufacturing facilities in Ras Al Khaimah.

Julphar's transportation and shipping division, MenaCool, was launched in 2008 to transport the company's medicines across the MENA region. In 2011, Julphar crossed AED 1 billion in sales, an 11.3% growth from 2010. Julphar began producing biosimilars in 2012 and launched a new division, Julphar Diabetes Solutions,[6] becoming the only company in the Middle East and North Africa to locally produce Recombinant DNA (r-DNA), the raw material used to make insulin.[4] Julphar inaugurated its first facility on the African continent with the opening of Julphar Ethiopia in 2013.

The launch of Julphar Bangladesh took place two years later in 2015, which coincided with the launch of Julphar Life, the company's consumer division. In 2017, Julphar acquired IV fluid company, Gulf Inject[7] and officially opened a facility in Saudi Arabia in collaboration with its local partner, Cigalah Group. In 2018, Julphar signed an agreement with the Ministry of Health (United Arab Emirates) to ensure the availability of critical medical supplies during crisis situations.[8]

Julphar won the Association of Strategic Alliance Professionals award in 2018 along with its partner, Merck & Co., becoming the first pharmaceutical company from the Middle East and Africa to win such an award.[9] The company also won the Frost & Sullivan 2018 Best Emerging GCC Pharmaceutical Manufacturing Company of the Year award.[10]

Facilities

Julphar has 16 production facilities.

Julphar UAE

Julphar UAE is based in Ras Al Khaimah and began operations in 1980. A total of 13 facilities produce tablets, capsules, pediatric powder suspensions (PPS), syrups, suspensions, vials, drops, ampoules, creams, ointments and suppositories.

Julphar Saudi Arabia

Julphar Saudi Arabia was launched in 2017 and is a joint venture between Julphar and its local partner, Cigalah Group. The facility was the first in King Abdullah Economic City to be awarded full cGMP certification on its first inspection by the Saudi Food and Drug Authority.[11]

Products

One of Julphar's leading products is Moist Exposure Burn Ointment (MEBO), a common product used for burns. The success of MEBO led to the creation of MEBO Scar, an ointment which was developed specifically by Julphar for the treatment of scars both old and new, and is used to restore the health of traumatized skin. MEBO Scar is used to treat functional and cosmetic issues caused by scarring.[12]

References

  1. ^ "Julphar holds Annual General Meeting".
  2. ^ Fact Sheet (Report). Julphar. 2015. Archived from the original on 2016-03-16. Retrieved 2015-04-20.
  3. ^ "Julphar Gulf Pharmaceutical Industries - What We Do". Julphar.net.
  4. ^ a b "UAE-produced insulin now available in 17 countries". Gulf Business. 12 July 2017.
  5. ^ "Julphar named top pharma company in UAE". tradearabia.com.
  6. ^ "Julphar Gulf Pharmaceutical Industries - Our Journey". Julphar.net.
  7. ^ "UAE pharma giant posts $350m sales in 'challenging' market". ArabianBusiness.com.
  8. ^ "Ministry of Health and Prevention partners with Julphar to help reinforce UAE's medicine supplies during emergencies - Ministry of Health and Prevention - UAE". Mohap.gov.ae. Retrieved 21 April 2019.
  9. ^ "News". Archived from the original on 2019-04-21. Retrieved 2019-04-21.
  10. ^ "Julphar wins Frost & Sullivan 2018 Award". Wam.ae.
  11. ^ "Julphar KSA Granted CGMP Certification". Archived from the original on 2018-03-04. Retrieved 2019-04-21.
  12. ^ "Julphar launches MEBO Scar to Middle East pharmaceutical market | Julphar". AMEinfo.com. 2012-05-03. Retrieved 2012-05-07.

External links

Categories